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Abstract
Allergen Specific Immunotherapy (SIT) for respiratory allergic diseases is able to significantly improve symptoms as
well as reduce the need for symptomatic medication, but SIT also has the capacity for long-term clinical effects
and plays a protective role against the development of further allergies and symptoms. The treatment acts on
basic immunological mechanisms, and has the potential to change the pathological allergic immune response. In
this paper we discuss some of the most important achievements in the documentation of the benefits of
immunotherapy, over the last 2 decades, which have marked a period of extensive research on the clinical effects
and immunological background of the mechanisms involved. The outcome of immunotherapy is described as
different levels of benefit from early reduction in symptoms over progressive clinical effects during treatment to
long-term effects after discontinuation of the treatment and prevention of asthma. The efficacy of SIT increases the
longer it is continued and immunological changes lead to potential long-term benefits. SIT alone and not the
symptomatic treatment nor other avoidance measures has so far been documented as the therapy with long-term
or preventive potential. The allergic condition is driven by a subset of T-helper lymphocytes (Th2), which are
characterised by the production of cytokines like IL-4, and IL-5. Immunological changes following SIT lead to
potential curative effects. One mechanism whereby immunotherapy suppresses the allergic response is through
increased production of IgG4 antibodies. Induction of specific IgG4 is able to influence the allergic response in
different ways and is related to immunological effector mechanisms, also responsible for the reduced late phase
hyperreactivity and ongoing allergic inflammation. SIT is the only treatment which interferes with the basic
pathophysiological mechanisms of the allergic disease, thereby creating the potential for changes in the long-term
prognosis of respiratory allergy. SIT should not only be recognised as first-line therapeutic treatment for allergic
rhinoconjunctivitis but also as secondary preventive treatment for respiratory allergic diseases.
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Allergy is a systemic disease with a local response fol-
lowing allergen exposure. Rhinitis, asthma and Bronchial
Hyperresponsiveness (BHR) are closely related and a
systemic pathway, involving the bloodstream and bone
marrow, contributing to the cross-talk between the
upper and lower airways [1].
The close relationship between allergic rhinitis and
allergic asthma and the co-morbidity of upper and lower
airway diseases has been carefully described elsewhere
[2-4]. In asthmatic children it has been shown that
asthma was more severe when in concomitance with
allergic rhinitis and that increased asthma medication
was required [5]. In asthmatic adults with concomitant
allergic rhinitis asthma control is less manageable while
there is a higher rate of asthma exacerbations and emer-
gency room visits [6]. Allergic rhinitis is a major risk
factor for the later development of asthma [3,7] and
more than 20% of all rhinitis patients develop asthma
later on in life [8]. Up to 50% of rhinitis patients have
increased bronchial hyperresponsiveness during, as well
as outside the pollen season [9] and an ongoing subcli-
nical level of inflammation [10]. Allergic sensitivities
usually increase with age [11] and being sensitised to
one allergen source also increases the risk for develop-
ing new sensitizations over time [12]. The understand-
ing of allergy as a chronic systemic immunological
condition should be the platform for the choice of diag-
nostic, treatment as well as monitoring options in the
allergic patient.
Allergen specific immunotherapy (SIT) produces a
decrease in symptoms and in the need for medication,
but SIT also has the capacity for long-term clinical
effects and for the prevention of the development of
further allergies and symptoms. The treatment acts on
the basic immunological mechanisms responsible for
causing symptoms and has the potential to change the
immune response and the pathological pathways respon-
sible for the allergic symptoms [13]. SIT is an anti-
inflammatory, causal and preventive treatment for
respiratory allergic diseases [14].
The year 2011 marked the 100th anniversary of the first
publication on SIT by Leonard Noon [15]. Since then,
SIT has been widely used in the treatment of respiratory
allergic diseases - at first on a more or less empirical
basis. For a number of years the treatment has progres-
sively evolved along with greater medical and immunolo-
gical insights. Basic immunological research, specific
knowledge about allergic diseases and intensive research
related to the allergenic molecules and the extracts used
for diagnosis and therapy have been continuously devel-
oped and as a result improved the opportunities for spe-
cific treatment of respiratory allergic diseases [16,17].
More recently the regulatory environment has evolved
and allergen extracts are regarded as pharmaceutical spe-
cialties with an increased need and request for documen-
tation and clinical data on effectiveness and safety
[18,19].
This paper highlights and examines some of the most
important developments and information regarding the
potential benefits of SIT achieved over the last 10-20
years - a period marked by much clinical activity,
explorative as well as confirmative studies on SIT and the
publication of international guidelines to support clinical
practice [4,20-22]. Although the use of sublingual immu-
notherapy (SLIT) with the commercial availability of new
products represents the most recent and well documen-
ted form for immunotherapy, the majority of explorative
studies on basic immunology, mechanisms of application
of allergen products and long-term clinical potential have
been performed using the original subcutaneous immu-
notherapy (SCIT) treatment concept. All these studies
which have been performed mainly based on scientific
interest, have established a very important basis for the
design of guidelines for production of the basic clinical
documentation on efficacy and safety of new product. It
is of paramount importance that in the new wider docu-
mentary immunotherapy studies we also seek confirma-
tion of the knowledge we have achieved over the many
years of investigator driven data exploration.
SIT - mechanism of action
Different immunological effector cells are responsible for
allergic inflammation [23-25]. The allergic disease is dri-
ven by a subset of T-helper lymphocytes (Th2), which
are characterised by the production of cytokines like IL-
4, IL-5 and IL-13 among others. These cells and their
cytokines are responsible for the effects on other cells
involved in the allergic response. The most important
effector cells in the allergic immunological response are
eosinophils, mast cells and basophils. Th2 cells play an
essential role in the promotion of allergen-specific IgE
synthesis by B cells.
The benefits and the clinical effects of SIT should be
evaluated and analysed in terms of the immunological
changes that follow the treatment. SIT acts by influen-
cing basic immunological mechanisms [26] resulting in
the suppression of the seasonal increase in eosinophilia
[27], in reduction of the late-phase reactivity [28,29] and
a shift from a Th2- to Th1-like response is initiated and
maintained [30-33]. T regulatory cells play a central role
in the mechanism of effective SIT with an important
effect on the down regulation of the Th2 response [34].
One mechanism by which immunotherapy suppresses
the allergic response is through an increase in the pro-
duction of specific IgG antibodies, primarily of the IgG4
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appearance of IgG4 antibodies is usually associated with
a decrease in symptoms. This is likely to be due, at least
in part, to an allergen-blocking effect at the mast cell
level and/or at the level of the antigen-presenting cell
(preventing IgE-facilitated activation of T cells) [35].
Because the production of IgE against normally harmless
antigens is the cause of the allergic responses, the pro-
duction of antigen specific IgG antibodies, can antagonise
and block the allergic inflammatory cascade resulting
from antigen recognition by IgE. Therefore, the shift in
balance between IgE and IgG4 is essential to successful
allergen SIT. It has been demonstrated that allergen-spe-
cific IgG4 antibodies with potent inhibitory activity
against IgE persist after treatment discontinuation and
could account for long-term clinical tolerance [36].
Induction of specific IgG4 has the capacity to influence
the allergic response in different ways (Figure 1), and is
related to immunological effector mechanisms, also
responsible for the reduced late-phase hyperreactivity
and ongoing allergic inflammation. Details are described
in Textbox 1.
Studies have shown that symptomatic improvement
correlates with reductions in eosinophils and IL-5 expres-
sion in the nasal mucosa [32] during the pollen season, as
well as with increased interferon-gamma (INF) produc-
tion [37]. Immunotherapy induces an IL-12-response
shown to be inversely related to IL-4 production and to
promote a Th1-response estimated as interferon-gamma
production which promotes B-cells into IgG production
[31]. Several studies have shown that immunotherapy
induces a new regulatory T-cell response characterised
by induction of IL-10 [38,39] which precedes the inhibi-
tory IgG4 antibody activity [40]. TGF-b is also a T-regu-
latory cell mediator induced by immunotherapy [41]
which is responsible for the down regulation of the Th2
response - reducing IL-5 production [33] and preventing
allergen-exposure-induced eosinophilia and inflamma-
tion [32]. The importance of T regulatory cells in allergy
and in relation to immunotherapy has been carefully
Figure 1 The immunological response to allergen specific immunotherapy. The immunological response to allergen specific
immunotherapy.
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basic immunological changes during immunotherapy.
The immunological mechanisms described here illustrate
the close connection between the basic immunological
response to immunotherapy and the humoral response,
characterised by the induction of competitive specific
antibodies accompanying and potentially leading to clini-
cal benefits.
Textbox 1
Different IgG4 related immunological effects acting as a
competitive response to that of specific IgE, result in
clinical effects as reduction in symptoms and the need
for medication, and a reduced inflammatory response to
allergen presentation (Figure 1).
Inhibition of mediator release
￿ Inhibition of mediator release could be caused by
direct inhibition of the allergen-IgE interaction or
through co-aggregation of the inhibitory FcgRIIB and
FcgRI [44]
￿ SIT-induced IgG inhibited histamine release from
basophils [45]
Blocking antibody
￿ Specific IgG antibodies acts by a “dilution” of the anti-
gen exposure to specific IgE antibodies by binding to
epitopes on the surface of the allergen, and thereby
directly reducing the antigen presenting capacity by the
relevant cell types [46]
Facilitated Antigen Presentation (FAP)
￿ IgE-facilitated antigen presentation results in the acti-
vation and subsequent proliferation of allergen-specific
T-cells at extremely low concentrations of allergen and
activates Th2 cells which then produce important cyto-
kines (IL-4, IL-13) inducing further IgE synthesis [47]
￿ Immunotherapy-induced specific IgG antibodies can
also affect and inhibit IgE- facilitated antigen presenta-
tion (FAP) and activation of Th2-cells, and thereby sig-
nificantly reduce the allergic response [23,45,48]
There is a time dependence in serum inhibitory activity
of Facilitated Antigen Binding which seem to be consis-
tent with the continued increase in clinical benefits fol-
lowing prolonged treatment with immunotherapy [49]
Clinical effectiveness of SIT
The first priority for respiratory allergic patients is
usually the treatment of allergic symptoms as these
appear as a consequence of allergen exposure. Different
symptomatic drugs have the capacity to reduce the symp-
toms either on a rescue basis or when taken daily [4,22].
From a regulatory point of view the primary focus on the
benefit from anti-allergic treatments is usually on the
potential reduction in symptoms. Together with the
potential range of benefits following SIT, reduction in
symptoms is mandatory. Recently, an overview of how
effective SIT is in reducing symptoms including a com-
parison to the effectiveness of symptomatic treatment
options was published [50]. The data support that already
during the first seasonal exposure after initiation of SCIT
a reduction in symptoms at least as potent as the reduc-
tion following treatment with symptomatic drugs can be
achieved.
Together with the significant reduction in allergic
symptoms, several studies on SIT have documented a sig-
nificant reduction in the need for symptomatic drugs on
short term as well as during long-term treatment [51-54]
even in patients with severe allergic rhinoconjunctivitis,
who fail to respond adequately to symptomatic treatment
[55]. The reduction in symptomatic medication achieved
early after initiation of treatment with SIT has been
shown for pollens [52] as well as perennial allergens [56].
Also, the long-term benefit even after termination of SIT
has been shown [57,58]. The most comprehensive over-
view of the outcome on reduction of the need for symp-
tomatic medication is provided by the recent Cochrane
reviews covering SIT studies with subcutaneous and sub-
lingual application of SIT for rhinoconjunctivitis as well
as asthma [59-61]. If patients were sensitised to other
allergens, this did not influence the response to the treat-
ment for their grass allergy [55], suggesting that SIT can
be efficiently used even in polysensitised patients. Both
adults and children with house dust mite-induced allergic
asthma, benefit from SIT which results in a steroid-spar-
ing effect by following guideline-defined asthma control
[62,63]. This is of particular importance as allergic
asthma is frequently associated with rhinitis [64] with the
consequent need of simultaneous nasal steroid therapy as
well as some concern arising from possible adverse
effects of long-term treatment with inhaled steroids in
children [65].
Endpoints and combined symptom and medication score
in SIT trials
The World Allergy Organization has proposed a model
for the standardisation of clinical trials of allergen speci-
fic immunotherapy for respiratory allergic symptoms
[21]. They suggest defining the primary outcome of
immunotherapy trials as the total clinical score, calcu-
lated as the sum of symptom score plus drugs usage cal-
culated as one score. The European Medicines Agency
(EMA guideline “Guideline on the clinical development
of products for specific immunotherapy for the treatment
of allergic diseases”) has also described the issues that the
use of rescue medication has a direct impact on symptom
severity [18]. An estimate of the power as well as the
number of subjects to be included is mandatory to the
outcome of clinical studies and the primary endpoint of a
clinical study should be the variable capable of providing
the most clinically relevant and convincing evidence
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also mandatory in confirmative clinical trials to define
the endpoint up front. It may sometimes be desirable to
use more than one primary variable, each of which could
be sufficient to cover the range of effects of the therapies.
For clinical trials on allergen specific immunotherapy this
could be the use of symptom score as well as medication
score reduction [66]. The extent of inter correlation
among the proposed primary variables may be
considered.
Different methods for combining symptom score and
intake of rescue medication have been described [66,67]
but there is no guideline for how this combined score
should be established, and from case to case the method
used must be pre-specified and justified. In order to
further develop the methods for one and only one final
endpoint for trials on SIT, new methods to establish a
clinical relevant score evaluating the potential reduction
in allergic symptoms in combination with the potential
reduced need for symptomatic medication have been
assessed [51,68,69]. Recently, the first validation of a
combined symptom/medication score strategy was pub-
lished as the “Allergy-Control-SCORE™”.B a s e do na
comparison of the symptoms and need for medication
during the pollen season between allergic subjects and
healthy controls, they proved a reliable instrument in
distinguishing between allergic patients and controls,
which is also able to access the severity of disease [70].
After the final endpoint has been defined and the results
obtained, it is possible to look for secondary parameters
and explorative outcomes which are extremely useful for
the establishment of new hypotheses and future research
[66,71].
Clinical effect levels
In this paper the effects of immunotherapy are cate-
gorised into the following levels of benefit whose immu-
nological characteristics are explained above.
￿ Early effect - reduction in symptoms/need for
medication
￿ Progressive effect - further reduction in symptoms/
need for medication and reduction in hyperresponsive-
ness/late-phase response
￿ Persistent effect - long-term reduced symptoms/need
for medication long-term reduced hyperresponsiveness/
late phase response after end of treatment period
￿ Preventive effect - prevention of new sensitivities
and progression of disease (rhinitis into asthma)
￿ Immunological effect - immune modulation and tol-
erance - immunological changes that lead to a poten-
tially curative effect
These correspond to the different levels of clinical
effects which can be claimed for the registration of
products for SIT as defined by the EMA [18] (Textbox 2).
Evidence for the different claims is summarised below.
Textbox 2
Depending on the clinical documentation available and
study duration different claims for efficacy are possible:
￿ Treatment of allergic symptoms: Short term clinical
trials conducted to show efficacy in the first pollen sea-
son after commencing specific immunotherapy or to
show efficacy in perennial allergies after some months
of treatment
￿ Sustained clinical effect: Maintenance of significant
and clinically relevant efficacy over two to three treat-
ment years
￿ Long-term efficacy and disease modifying effect: Sus-
tained significant and clinically relevant efficacy in post-
treatment years
￿ Curing allergy: Sustained absence of allergic symp-
toms in post-treatment years
Early effect -reduction in symptoms/need for medication
It is evident that very early on and during the first seaso-
nal exposure after initiation of immunotherapy -or alter-
natively when patients have reached the top or
maintenance dosage [30,55,72,73], they experience an
improvement in allergy symptoms (rhinoconjunctivitis
and/or asthmatic symptoms) and a need for rescue medi-
cation. The early effect of SIT on rhinoconjunctivitis
symptom scores has been confirmed in the so-called “big
trials” which recruited hundreds of grass pollen allergic
patients [55,74,75]. In sublingual tablet studies the posi-
tive effects of at least 16 weeks of treatment have been
documented [74,75] and a single study using an adjuvant
(MPL) in combination with a grass allergen extract also
indicate efficacy after only 4 weeks with 4 injections
[76,77].
Pre-seasonal short-term therapy normally including six
weeks of treatment has been shown to be clinically
effective as early as in the first season [51,78-80]. A six-
month treatment period with recombinant grass pollen
major allergens has also proved effective [81]. A com-
bined symptom/medication score strategy has recently
been used and confirmed the clinical efficacy for short
term injection therapy [51,68], as well as for sublingual
tablet treatment [66].
Progressive effect - further reduction in symptoms/need
for medication and reduction in hyperresponsiveness/
late-phase response
During a long-term treatment period of up to four years,
persistent effects and further increased clinical and
immunological benefits are achieved. This has been
shown for grass, cat and dog, and house dust mites
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short-courses of a grass pollen allergoid, using a com-
bined symptom medication score it was clear that
although the treatment was clinically effective in the first
season, its clinical efficacy was even better in the second
seasonal [51]. An open continuation of this study includ-
ing a third pre-seasonal treatment period confirmed the
increased efficacy potential which prolonged immu-
notherapy treatment provides [54]. When continuing the
treatment for more than 12 months it is possible to intro-
duce non-specific efficacy parameters, seen as a decrease
in the patient’s non-specific bronchial hyper responsive-
ness as an indicator of inflammation. This was shown in
patients suffering from house dust mite related allergic
asthma, who increased their tolerance to bronchial chal-
lenge with house dust mite allergen after six months, but
it was only after 18 months of SIT that a persistent
reduced bronchial inflammation and hyperresponsiveness
measured by bronchial challenge with metacholine was
found [84]. It has also been observed that two years of
immunotherapy prevented the seasonal onset of bron-
chial hyperresponsiveness in grass pollen allergic patients
with rhinitis and asthma [29]. According to a meta-analy-
sis on asthma, SCIT significantly reduced allergen speci-
fic bronchial hyperresponsiveness, which was evaluated
in the majority of the studies done after one year of treat-
ment [61]. The finding that SIT is able to improve speci-
fic bronchial hyperreactivity is important from a clinical
point of view. Indeed, patients with brittle allergic asthma
are at risk of sudden deterioration when exposed to
increased levels of an aeroallergen to which they are sen-
sitive, as in the case of mould allergic patients. Currently,
the measurement of BHR is the only accurate method of
assessing such a risk and any intervention which reduces
the risk of an acute episode of asthma under these cir-
cumstances would be clinically useful. Moreover, a high
percentage of children and adults also develop a late
asthmatic response after an allergen specific bronchial
challenge [85], the presence of which is considered an
experimental model close to resembling chronic bron-
chial allergic inflammation. Subcutaneous SIT is able to
decrease not only early, but also late asthmatic responses
following allergen specific bronchial challenge, thus con-
firming the anti-inflammatory effect of the treatment in
the lung [53].
A Th2/Th1 response towards normal balance is usually
associated with a positive clinical effect of immunotherapy.
In grass pollen allergic patients undergoing injection immu-
notherapy it has been shown that a significant change
towards a Th1 response measured by the level of inter-
feron-gamma in peripheral blood was achieved after a 12-
month treatment period, but not after just three months
treatment -despite a well-documented symptomatic effect
being found after three months [30]. Administering a short
four-week therapy with a grass allergen extract together
with an MPL adjuvant showed that specific IgG and IgG4
levels increased only slightly in year one of SIT, but which
became highly significant in year two [86]. A progressive
immunological change as indicated by the significant
induction of non-IgE competitive antibodies was also
observed in year two of treatment with a sublingual tablet
for grass pollen allergy whose clinical efficacy comparable
to the benefits of year one [87]. In a three-year long-term
SIT study in grass allergic patients with both rhinoconjunc-
tivitis and asthma the asthma symptoms had completely
cleared after 3 years with a general progression in clinical
effect over the years. Symptoms and the need for medica-
tion was generally reduced from the beginning although
nasal symptoms were not reduced during the first season -
again indicating that continuing the treatment will increase
the benefits [88].
Persistent effect -long-term reduced symptoms/need for
medication -long-term reduced hyperresponsiveness/late-
phase response after end of treatment period
Recently, wider studies have confirmed the long-term clin-
ical potential of SIT after termination of treatment. In the
Preventive Allergy Treatment Study (PAT) children trea-
ted for 3 years with pollen immunotherapy (grass and/or
birch) showed a consistent reduction in their symptom
score rated by Visual Analogue Score (VAS) and by objec-
tive measures of conjunctival sensitivity (CPT). The chil-
dren were tested respectively two and seven years after
discontinuation of treatment [89,90]. The sustained long-
term and disease-modifying effects of immunotherapy
have also been confirmed in a large-scale randomised,
double-blind, placebo-controlled sublingual trial with a
two-year follow-up after three consecutive years of treat-
ment with a sublingual grass allergen tablet [58,91]. The
key study which confirms the long-term persistent clinical
and also immunological effect measured on late-phase
skin response to an allergen, is the double blind rando-
mised study where patients treated for grass pollen allergy
with SCIT over a three-to-four year span were followed
up to three years after cessation of therapy and compared
to a SCIT naive matched group of patients [57]. Other stu-
dies have shown up to eight years persistent long-term
clinical effects after termination of two to three years of
SIT for grass pollen, tree pollen, animal hair and dander
and house dust mites [92-96]. In cat allergic patients with
mild to moderate asthma not only was the reactivity to cat
allergen reduced following immunotherapy, but also a
reduction in specific as well as non-specific hyperrespon-
siveness occurred during the five-year follow up period
[94]. In a small open controlled three year consecutive
pre-seasonal treatment study with an allergoid persistent
clinical efficacy in children for as long as up to 12 years
after discontinuation of the treatment was shown [97,98].
Jacobsen et al. Clinical and Translational Allergy 2012, 2:8
http://www.ctajournal.com/content/2/1/8
Page 6 of 11Preventive effect -prevention of new sensitivities and
progression of disease (rhinitis into asthma)
Evidence for prevention of asthma - the PAT study and
background
The Preventive Allergy Treatment study (PAT) [9] was the
first large prospective randomised controlled long-term
follow-up study designed to show whether SIT can pre-
vent the development of asthma in children suffering from
seasonal allergic rhinoconjunctivitis caused by allergy to
birch and/or grass pollen. SIT was administered for three
years, after which the children were evaluated for the
development of asthma. Metacholine bronchial provoca-
tion tests were carried out during the relevant season(s)
and during winter. Unexpectedly, as a consequence of the
careful study examination at baseline, before commencing
SIT, it was found that 20% of the children had undiscov-
ered mild asthmatic symptoms during the pollen season
( s ) ,a n dt h a tm o r et h a nat h i r dh a ds i g n i f i c a n ts e a s o n a l
ongoing bronchial hyperresponsiveness as revealed by
metacholine challenge. Among those without asthma at
baseline, the group treated with SIT showed a significant
positive odds ratio for reducing the risk for development
of asthma (odds ratio 2.52; p < 0.001). Another study
using sublingual immunotherapy with grass allergen
extract for 3 consecutive years also showed potential for
the prevention of developing new asthma in children dur-
ing the treatment period [99]. In this open randomised
trial in children aged 5-14 years, patients were treated
with a standardised mixture of 5 grasses. The PAT study
initiative was based on a list of clinical studies which had
all shown preventive potential. Among these, the classic
14-year long-term follow up s t u d yi nc h i l d r e nb yJ o h n -
stone and Dutton who investigated SIT for the prevention
of exacerbation and development of asthma. A highly sig-
nificant reduction in the number of patients with asthma
was reported at the time of follow-up which corresponded
to the date of the children’s1 6
th birthday. Only 22% of the
placebo treated children were free of asthma compared to
72% of the SIT treated children. The children were initially
treated for four years with individual mixtures of allergens
and the clinical effect as well as the potential prevention of
asthmatic symptoms was dose related - the strongest
being in children who received the highest doses of aller-
gen [100]. In a two-year placebo controlled study on the
effect of immunotherapy in patients with allergic rhino-
conjunctivitis caused by house dust mite allergy, the
authors had selected children and adults with coexisting
BHR. Besides the finding that immunotherapy reduced the
provocative dose of metacholine 4-fold, they also reported
that none of the SIT treated patients had developed symp-
toms of asthma during the 2 year study period [101].
Evidence for the prevention of new allergies
A ne a r l ys t u d yb yJ o h n s t o n es h o w e dt h a tS C I Tc o u l d
reduce the risk of development of new allergic
sensitisations as they found that no children during a 4
year course of high dose immunotherapy developed new
IgE sensitisations compared to 25% of those in the con-
trol group [102]. In the last two decades several studies
using SIT have confirmed such findings. Two studies
have shown the reduction in new sensitisations in chil-
dren who were treated for house dust mite allergy.
In one study, monosensitised children treated for
three years with SIT compared to non-treated controls,
showed a significant reduction in the development of
new allergic sensitivities (45% developed no new sensiti-
s a t i o n sa ta l l )a l t h o u g hn o n eo ft h ec o n t r o lp a t i e n t s
remained free of the development of one or more new
sensitisations [103]. In the other study measuring sensi-
tisations to inhalant allergens three years after termina-
tion of house dust mite immunotherapy, two thirds of
the control group children had developed one or more
new sensitisations revealed by skin prick testing and
specific IgE compared to only a quarter with new sensi-
tivities in the SIT group [104].
A very large follow-up study including more than 7182
monosensitised patients with different allergies and with
allergic rhinitis and/or asthma were treated with SCIT
for four years and compared to 1214 open controls trea-
ted only with symptomatic drugs. Sixty-eight percent of
controls had developed one or more new sensitisations
compared to 27% in immunotherapy treated patients and
at a follow-up visit three years after termination of the
treatment period, 75% of controls had developed new
sensitizations compared to 25% in the active group [105].
In a group of children with grass allergy followed up for
12 years the data revealed fewer new allergies in the
active group treated with a consecutive three year pre-
seasonal short-term treatment compared with controls
[98,99]. Most studies on prevention of new sensitizations
have been performed using SCIT, but SLIT has also
shown its potential for reducing the risk for new allergies
from 38% of control group patients to 5.9% of actively
treated patients [106].
Evidence for long term prevention
T h el o n gt e r ma s t h m ap r e v e n t i v ep o t e n t i a lo fS I Tw a s
first described in a tree pollen immunotherapy study in
which 36 adult patients received immunotherapy. During
the long-term six year follow-up period after the termina-
tion of treatment with standardised tree pollen allergen
extracts for two years, none of the patients initially suf-
fering from rhinitis alone had developed asthma during
the eight-year study period [94]. The five and ten year
follow-up of the PAT study are the first prospective fol-
low-up studies testing whether SIT can prevent the long-
term development of asthma and whether the clinical
effects persist in children suffering from seasonal allergic
rhinoconjunctivitis caused by allergy to birch and/or
grass pollen as these children mature. After the total SIT
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development of asthma and then re-evaluated after a
total of five years. The evaluation showed that immu-
notherapy reduces progression from allergic rhinocon-
junctivitis to asthma after three years of SIT [9] and at
the five year follow-up two years after SIT termination
[89]. The actively treated children had persistently signifi-
cantly less asthma at the five year follow-up (odds ratio
3.1; p < 0.01). The significant improvements in allergic
rhinoconjunctivitis symptom and medications scores as
well as in the conjunctival sensitivity to birch and grass
observed to persist at five-year follow-up, also persisted
at the ten-year follow-up. As at the five-year follow-up,
fewer actively treated subjects had developed asthma at
the ten-year follow-up (odds ratio 2.5 (1.1-5.9) [90]. After
the complete study, the longitudinal treatment effect
including all observations at three-, five- and ten-year fol-
low-up was highly statistically significant (p = 0.0075) and
the odds ratio for not developing asthma was 4.6 (95% CI
(1.5; 13.7)) in favour of SIT over the ten-year period. The
study also showed that bronchial hyperresponsiveness at
baseline was associated witha ni n c r e a s e dr i s ko fl a t e r
development of asthma (p = 0.002) and in children with
seasonal allergic rhinitis evaluation of BHR should be
recommended in the indication for immunotherapy.
Only SIT has a long term and preventive potential
Neither symptomatic treatment nor different avoidance
measures for allergy have so far documented the long-
term or preventive benefits. Various strategies for the pre-
vention of the development of allergic rhinoconjunctivitis
and asthma have been proposed including allergen avoid-
ance, pharmacological treatment (antihistamines and ster-
oids) and SIT. Allergen avoidance is hardly applicable for
many allergen sources and only a limited reduction in
exposure can be achieved by modification of life habits
(Prevention of Allergy and Allergic Asthma -WHO/WAO
Geneva, 2002) [107]. Secondary prevention addressing
children suffering from atopic dermatitis to prevent
respiratory symptoms and further disease progression into
asthma involves traditional pharmacotherapy with antihis-
tamines. While treatment with antihistamines does pro-
vide symptomatic relief, it does not modify long term
outcomes in children as the natural course of the disease
is not altered. A recent large multi-centre trial in which
children with atopic dermatitis were given cetirizine, failed
to reduce the development of asthma [108].
A potential tertiary preventive measure for worsening
of asthma through early treatment with inhaled steroids
in children with episodic wheezing has been suggested,
but recent studies on the capacity of inhaled steroid
therapy during early symptomatic episodes of wheezing
to delay progression to persistent disease have failed to
show any preventive potential [109,110].
Conclusion
Allergen specific immunotherapy is the only treatment
that interferes with the basic pathophysiological
mechanisms of the allergic disease and thereby carries
the potential for changes in the long-term prognosis of
respiratory allergy. SIT should be recognised not only as
first-line therapeutic treatment for allergic rhinocon-
junctivitis but also as secondary preventive treatment for
respiratory allergic diseases. Together with the long
term clinical experience available, SIT is an important
treatment for prevention of asthma in patients with
allergic rhinitis and it makes asthma control easier to
accomplish. Immunotherapy seems to reduce the devel-
opment of new allergic sensitivities as measured by skin
prick test as well as specific IgE measurements, and
long term follow-up on immunotherapy studies demon-
strate that specific immunotherapy with modern phar-
maceutically standardised allergen extracts shows
persistent long term effect on clinical symptoms after
termination of treatment and long-term, preventive
effect on later development of asthma in children with
seasonal rhinoconjunctivitis. These are important added
benefits to the immediate clinical effect which is com-
parable to other treatment options and has shown to
progressively improve during treatment periods. It is so
far the only treatment for allergic diseases which has
shown to be able to prevent worsening of disease and
development of asthma. In these years, a number of
large ongoing clinical studies with the primary purpose
of establishing the EMA guideline documentation
needed for registration of pharmaceutical products will
certainly add further to our basic knowledge about the
potential immunological modifications and long-term
options. This is of great importance for the optimization
of the future treatment of the increasing number of
patients suffering from respiratory allergic diseases.
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